Summary of allogeneic SCT
| . | t(8;21) (n = 194), no. . | inv(16), (n = 66), no. . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| RIST | 31 | 9 | .66 |
| Myeloablative | 161 | 56 | |
| GVHD prophylaxis* | |||
| sMTX+CyA | 136 | 48 | .78 |
| sMTX+FK | 20 | 8 | |
| HLA | |||
| Match | 146 | 47 | .5 |
| Mismatch | 45 | 18 | |
| Donor | |||
| Related | 161 | 44 | .004 |
| Unrelated | 32 | 22 | |
| Stem cell source | |||
| BM | 101 | 40 | .27 |
| PB | 72 | 17 | |
| CB | 18 | 7 | |
| aGVHD grade | |||
| 0-I | 117 | 37 | .54 |
| II-IV | 60 | 22 | |
| cGVHD type | |||
| None | 64 | 28 | .28 |
| Lmt/Ext | 67 | 20 |
| . | t(8;21) (n = 194), no. . | inv(16), (n = 66), no. . | P . |
|---|---|---|---|
| Conditioning regimen | |||
| RIST | 31 | 9 | .66 |
| Myeloablative | 161 | 56 | |
| GVHD prophylaxis* | |||
| sMTX+CyA | 136 | 48 | .78 |
| sMTX+FK | 20 | 8 | |
| HLA | |||
| Match | 146 | 47 | .5 |
| Mismatch | 45 | 18 | |
| Donor | |||
| Related | 161 | 44 | .004 |
| Unrelated | 32 | 22 | |
| Stem cell source | |||
| BM | 101 | 40 | .27 |
| PB | 72 | 17 | |
| CB | 18 | 7 | |
| aGVHD grade | |||
| 0-I | 117 | 37 | .54 |
| II-IV | 60 | 22 | |
| cGVHD type | |||
| None | 64 | 28 | .28 |
| Lmt/Ext | 67 | 20 |
Correlation between the two groups was examined. Some of the missing data was not available, and total numbers do not add up to the number of the patients in each group.
RIST indicates reduced intensity stem cell transplantation; sMTX, short-course methotrexate; CyA, cyclosporin A; FK, tacrolimus; BM, bone marrow; PB, peripheral blood; CB, cord blood; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Lmt, limited; and Ext, extensive.
Dose of methotrexate was not surveyed in the study. Detail of other GVHD prophylaxis regimens are in Table S1.